FDA - Spark Newswire

1 minute read

Why Are Apellis Pharmaceuticals Shares Trading Higher Today?

Today, 6:34 PM

The FDA approved Apellis Pharmaceuticals Inc’s (NASDAQ:APLS) Syfovre (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Syfovre…

APLS

1 minute read

Why CVRx Stock Is Plunging Today

By Vandana Singh

Today, 6:34 PM

CVRx Inc (NASDAQ:CVRX) announced the preliminary topline results of the BeAT-HF (Baroreflex Activation Therapy for Heart Failure) post-market randomized clinical trial.…

CVRX

1 minute read

Aileron Therapeutics Announces Termination Of Phase 1b Breast Cancer Chemoprotection Trial And Exploration Of Strategic Alternatives

By Bill Haddad

Today, 6:34 PM

Aileron Therapeutics (NASDAQ:ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial

ALRN

4 minute read

Yield10 Bioscience Announces Key Advancements In The Development Of Herbicide Tolerant Camelina Supporting Large Acreage Production Of Low-Carbon Intensity Feedstock Oil For The Biofuel Market

By Happy Mohamed

Today, 6:34 PM

-Second field trial confirms Camelina tolerance to over-the-top herbicide application -Greenhouse studies support proof-of-concept for stacked herbicide traits in Camelina -Yield10 filed RSR under USDA-APHIS's

YTEN

1 minute read

89bio To Present Additional Pegozafermin Data In Severe Hypertriglyceridemia From Phase 2 ENTRIGUE Study At American College Of Cardiology’s Annual Scientific Session Together With World Congress Of Cardiology

By Happy Mohamed

Today, 6:34 PM

89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today

ETNB

2 minute read

Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment

By Vandana Singh

Today, 6:34 PM

The FDA granted accelerated approval to Travere Therapeutics Inc’s (NASDAQ:TVTX) Filspari (sparsentan) to reduce proteinuria in adults with primary IgAN at risk…

CSLLY

1 minute read

Akebia Therapeutics Received Interim Response From The FDA To Appeal For Vadadustat For The Treatment Of Anemia Due To Chronic Kidney Disease

By Happy Mohamed

Today, 6:34 PM

Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company received a second interim

AKBA

1 minute read

FDA
News

Regeneron Says Pozelimab (C5 Antibody) BLA For Treatment Of Children And Adults With Ultra-rare CHAPLE Disease Accepted For FDA Priority Review

By Benzinga Newsdesk

Today, 6:34 PM

Regeneron announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for pozelimab as a treatment for adults and children as young as 1 year of age with

REGN